Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase 3 Clinical Trial of ARVN003 (MicroLine) for Presbyopia in China

Eyenovia announced that its strategic partner, Arctic Vision, enrolled the first patient in its Phase 3 clinical trial of ARVN003 (MicroLine) for presbyopia. This marks the first time that a clinical trial has been approved in China to evaluate a pharmacologic treatment for presbyopia.

In August 2020, Arctic Vision obtained from Eyenovia an exclusive license for the development and commercialization of ARVN003 (MicroLine) in Greater China and South Korea. The exclusive license agreement also included Eyenovia’s development-stage candidate for pediatric progressive myopia, MicroPine. Subsequent to this original agreement, Arctic Vision also licensed Eyenovia’s development-stage candidate for pharmacological mydriasis, MydCombi. Eyenovia is currently preparing a New Drug Application to obtain marketing approval for MydCombi in the United States.

“We are very pleased that our partner, Arctic Vision, has achieved this significant milestone with the dosing of the first patient in its Phase 3 presbyopia program,” stated Dr. Sean Ianchulev, chief executive officer and chief medical officer of Eyenovia. “Presbyopia represents a significant and growing market opportunity in China and South Korea, driven by many of the same factors that we see here in the US—most notably an aging population and a growing number of people looking for alternatives beyond reading glasses or surgery.”

“In parallel, Arctic Vision continues work on its other two Eyenovia licensed programs—pediatric progressive myopia (MicroPine) and pharmacologic mydriasis (MydCombi). Pediatric progressive myopia, in particular, represents a significant unmet need in China; the Ministry of Education estimates that nearly 53% of all Chinese children suffered from myopia in 2020, and 13 million children are estimated to be at highest risk. Taken together, through this partnership, we believe we have the opportunity to help millions of people while generating potentially significant sales royalties for our company, should one or more of these programs receive regulatory approval.”